Zoetis (ZTS) Aandelenoverzicht
Zoetis Inc. houdt zich bezig met het ontdekken, ontwikkelen, produceren en op de markt brengen van geneesmiddelen, vaccins, diagnostische producten en diensten, biologische hulpmiddelen, genetische tests en precisieoplossingen voor diergezondheid voor de diergezondheidsindustrie in de Verenigde Staten en internationaal. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 5/6 |
| Toekomstige groei | 2/6 |
| Prestaties in het verleden | 4/6 |
| Financiële gezondheid | 3/6 |
| Dividenden | 5/6 |
Beloningen
Risicoanalyse
ZTS Community Fair Values
Create NarrativeSee what 225 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
Zoetis Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$75.35 |
| 52 Week Hoogtepunt | US$160.48 |
| 52 Week Laag | US$71.47 |
| Bèta | 0.75 |
| 1 maand verandering | -3.61% |
| 3 maanden verandering | -35.53% |
| 1 Jaar Verandering | -50.47% |
| 3 jaar verandering | -60.32% |
| 5 jaar verandering | -62.83% |
| Verandering sinds IPO | 142.99% |
Recent nieuws en updates
Narratiefupdate • Jul 22
ZTS: Premium Pet Health Portfolio Will Support Post Lawsuit And Guidance Reset
The analyst price target for Zoetis has been lowered, with the model fair value estimate moving from about $124.59 to $114.76, as analysts temper revenue growth assumptions while slightly improving profit margin and applying a lower future P/E multiple in response to a broad series of recent target cuts and more cautious commentary following Q1 results. Analyst Commentary Recent research on Zoetis shows a clear reset in expectations, with most analysts cutting price targets and recalibrating models after a difficult Q1 and updated guidance.
Nieuw narratief • Jul 20
Wall Street Shock vs. Clinical Ground Truth — Is Zoetis a Value Trap or a Generational Mispricing?
Zoetis may not always look like the most high-tech, flashy ticker on Wall Street, but as a practicing veterinarian, my hands-on clinical experience tells a very different story. Sixteen years ago, when I first earned my veterinary license, the very first product I administered was Zoetis’ Vanguard vaccine.Recent updates
Narratiefupdate • Jul 22
ZTS: Premium Pet Health Portfolio Will Support Post Lawsuit And Guidance Reset
The analyst price target for Zoetis has been lowered, with the model fair value estimate moving from about $124.59 to $114.76, as analysts temper revenue growth assumptions while slightly improving profit margin and applying a lower future P/E multiple in response to a broad series of recent target cuts and more cautious commentary following Q1 results. Analyst Commentary Recent research on Zoetis shows a clear reset in expectations, with most analysts cutting price targets and recalibrating models after a difficult Q1 and updated guidance.Nieuw narratief • Jul 20
Wall Street Shock vs. Clinical Ground Truth — Is Zoetis a Value Trap or a Generational Mispricing?
Zoetis may not always look like the most high-tech, flashy ticker on Wall Street, but as a practicing veterinarian, my hands-on clinical experience tells a very different story. Sixteen years ago, when I first earned my veterinary license, the very first product I administered was Zoetis’ Vanguard vaccine.Seeking Alpha • Jul 14
Zoetis: Buy When There Is Blood In The Streets
Summary Zoetis has long been viewed as a high-quality compounder. However, after reaching an all-time high of $249.27 in December 2021, the stock is now caught in a ~70% drawdown. This can be primarily attributed to the dismal performance of the company's crown jewel asset, namely the U.S. companion animal business. After delivering an impressive 25% organic growth during the full year of 2021, the U.S. companion animal business reported dismal performance in Q1-26, with an organic decline of 11%. In addition to the declining health of the average U.S. consumer, management noted heightened competitive pressure from the introduction of both new products and generics. Zoetis is now trading at a free cash flow yield of ~7.3%, which is by far the highest since the company's IPO in February 2013. Organic growth for the full year of 2026 is now expected between 2.0% and 5.0%. Read the full article on Seeking Alpha
Narratiefupdate • Jul 08
ZTS: Depressed Sentiment Will Set Up Long-Term Premium Portfolio Recovery
The analyst price target for Zoetis has been revised down from about $184 to $160. This reflects lower modeled revenue growth, a slightly higher discount rate, and reduced future P/E assumptions, which are partly tied to recent sector wide target cuts and concerns around key products and consumer trade down.
Narratiefupdate • Jun 24
ZTS: Future Pipeline And New Therapies Will Restore Confidence
Zoetis' analyst-derived fair value has been reset from $127.00 to $90.00 as analysts factor in weaker growth assumptions, a lower future P/E, and softer margin expectations following recent price target cuts and downgrades tied to investor confidence and competitive pressures. Analyst Commentary Recent research on Zoetis points to a more cautious mood, with several bearish analysts focusing on valuation pressure, softer execution and questions around the strength of future growth.Analyse-artikel • Jun 20
Zoetis (ZTS) Stock Could Be 15.3% Undervalued After Class Action Lawsuits
Zoetis (ZTS) is back in focus after a series of securities class action lawsuits accused the company of misleading investors about weakening demand, safety concerns, and market share losses in its key companion animal products. See our latest analysis for Zoetis. At a share price of $78.71, Zoetis has seen pressure build over the past few months, with a 90 day share price return that declined 31.95% and a 1 year total shareholder return that declined 49.14%. Repeated class action...Narratiefupdate • Jun 10
ZTS: Premium Pet Health Portfolio Will Support Post Selloff Earnings Reset
Analysts have trimmed Zoetis' average price target by roughly $30 to $40 to around the low $100s. This reflects recent target cuts from firms citing softer Q1 results, intensifying competition, and a sharp pullback in the stock that has weighed on investor confidence.Narratiefupdate • May 26
ZTS: Premium Pet Health Portfolio Will Support Reset Earnings Path Forward
Zoetis' analyst fair value estimate has been reset from $151.00 to about $124.59 as analysts trim price targets after a difficult Q1, rising competitive pressures, and signs that premium pricing is meeting more cautious consumer demand, despite longer term guidance implying improvement. Analyst Commentary Recent research points to a reset in expectations for Zoetis, with target prices broadly trimmed as analysts rework their models around the latest Q1 update, rising competition, and more cautious consumer behavior toward premium products.
Nieuw narratief • May 26
Zoetis down -50% over the past year
World's leading animal pharma company at 13x PE with 9% EPS growth Occasionally something crosses my eye which screens well, but after some work is done it isn’t interesting enough to warrant writing about it as a paid article. Zoetis is one such stock.Narratiefupdate • May 03
ZTS: Share Repurchases And Capital Discipline Will Support Medium-Term Upside
Analysts have modestly trimmed their Zoetis fair value estimate by about $3 to $184, reflecting mixed updates to revenue growth, margins, and long term P/E assumptions after recent shifts in price targets and ratings across the Street. Analyst Commentary Recent research updates on Zoetis reflect a mix of reduced price targets, a downgrade on growth concerns, and fresh bullish coverage.Narratiefupdate • Apr 19
ZTS: Fair View Weighs Organic Growth Concerns Against Pipeline Execution Risk
Analysts have trimmed the Zoetis fair value estimate by $3 to $127, reflecting a mix of cautious views around organic growth and slightly adjusted assumptions for future P/E, revenue growth, and profitability, even as some firms maintain a bullish stance on the stock. Analyst Commentary Recent Street research around Zoetis shows a split tape, with several bearish analysts focusing on weaker organic growth trends and execution risk, even as others remain constructive on the long term story.Narratiefupdate • Apr 04
ZTS: Share Repurchases And Execution Recovery Will Support Medium-Term Upside
Analyst targets on Zoetis have shifted modestly, with a small net reduction in the Street price target in dollar terms as some analysts cite concerns about organic growth and an innovation "air pocket," even as others make minor upward adjustments. Analyst Commentary Recent Street research on Zoetis reflects a split view, with some analysts emphasizing concerns around organic growth and an innovation air pocket, while others are adjusting targets in a more constructive way.Narratiefupdate • Mar 21
ZTS: Future OA Pain Launch And Buybacks Will Support Medium-Term Upside
Narrative Update The updated analyst price target for Zoetis moves from about $197.51 to $187.59, reflecting analysts' mixed views. Some cite softer organic growth and an innovation "air pocket," while others make smaller price target adjustments.Narratiefupdate • Mar 06
ZTS: Fair View Balances Growth Concerns With Innovation Air Pocket Risk
Zoetis's analyst price target holds steady at $130, as analysts balance concerns about organic growth and an innovation "air pocket" with stable margin expectations and a lower future P/E assumption. Analyst Commentary Recent Street research on Zoetis points to a more cautious tone, with several bearish analysts questioning the near term growth setup and how that lines up with the current valuation.Narratiefupdate • Feb 20
ZTS: Future Pet Osteoarthritis Pipeline Will Support Premium Multiple Potential
Zoetis' analyst fair value estimate has been reset from $158.22 to $151.00, as analysts balance recent price target changes and a slightly lower assumed future P/E multiple against broadly steady growth and margin assumptions. Analyst Commentary Recent Street research on Zoetis points to a mixed setup, with some analysts seeing support for the current valuation and others focusing on execution risk and the product pipeline.Narratiefupdate • Feb 06
ZTS: Future OA Pain Launch Execution Will Drive Medium-Term Upside Potential
Analysts have trimmed their Zoetis fair value estimate from about US$200 to roughly US$197.51. This reflects recent price target cuts and more cautious views around product launch headwinds and competition, even as they still see solid margins and a premium P/E as part of the story.Narratiefupdate • Jan 22
ZTS: Fair Outlook Balances OA Pain Headwinds With New Antibody Approvals
Narrative update on Zoetis The analyst fair value estimate for Zoetis has been reset from US$153 to US$130 as analysts factor in slower expected revenue growth, a slightly higher discount rate, lower assumed future P/E multiples, and ongoing competitive and product launch headwinds highlighted in recent research. Analyst Commentary Recent research on Zoetis has tilted more cautious, with several bearish analysts resetting expectations around growth, execution, and what investors are willing to pay for the stock.Narratiefupdate • Jan 08
ZTS: Future Product Launches Will Offset Current Competition Pressures
Analysts have trimmed their price targets on Zoetis, reflecting a fair value move from about $170 to $158 as they factor in product launch headwinds, tougher competition in key franchises, and more cautious revenue expectations for 2025 and 2026. Analyst Commentary Recent Street research reflects a mixed but more cautious stance on Zoetis, with several firms trimming price targets and reassessing growth and competitive risks over the next few years.Narratiefupdate • Dec 15
ZTS: Execution In Animal Health Leadership Will Drive Medium-Term Upside Potential
Analysts have cut their fair value estimate for Zoetis by about $30,000,000,000 to roughly $200,000,000,000, reflecting expectations for slower mid decade revenue growth, modestly lower margins, and a less generous future earnings multiple amid increasing competitive and product launch headwinds. Analyst Commentary Recent Street research reflects a more balanced stance on Zoetis, with fair value expectations reset lower but many firms still highlighting the company as a structural leader in animal health.Narratiefupdate • Nov 30
ZTS: Earnings Will Recover As Competition Pressures Recent Product Launches
Zoetis's fair value target experienced a modest reduction to $169.96. Analysts highlighted competitive pressures and headwinds from recent product launches as key drivers for the change.Narratiefupdate • Nov 16
ZTS: Earnings Will Rebound As Volume Pressures Ease In 2026
Zoetis' analyst price target has been reduced from approximately $188 to $171 per share, as analysts cite tempered growth expectations and revised financial assumptions following recent quarterly updates. Analyst Commentary Following Zoetis' latest quarterly updates and subsequent guidance revision, analysts have updated their perspectives on the company's outlook.Narratiefupdate • Nov 01
ZTS: Global Demand Trends Will Drive Earnings Consistency In Coming Quarters
Narrative Update: Zoetis Analyst Price Target Adjustment Analysts have modestly decreased their price target for Zoetis from $165 to $158, citing a more cautious outlook ahead of upcoming results. Analyst Commentary Analyst perspectives on Zoetis highlight both optimism regarding the company’s long-term fundamentals as well as heightened caution leading into upcoming earnings releases.Narratiefupdate • Oct 18
Companion Animal And Livestock Demand Will Unlock Future Opportunities
Analysts have slightly lowered their price target for Zoetis from $189.22 to $188.83, citing modest revisions to revenue growth estimates. They also noted a marginal increase in expected profit margins.Narratiefupdate • Oct 04
Companion Animal And Livestock Demand Will Unlock Future Opportunities
Analysts have slightly lowered their price target for Zoetis from $190.29 to $189.22, citing marginally softer revenue growth and profit margin expectations. What's in the News Zoetis received conditional FDA approval for Dectomax-CA1, the first and only injectable for preventing and treating infestations caused by New World screwworm larvae in cattle.Seeking Alpha • Mar 25
Zoetis: Lots Of Growth Opportunities For This High-Quality Compounder
Summary Zoetis is currently cheap from a historical perspective, presenting a potential buying opportunity. The company operates in a growing animal healthcare market, benefiting from trends like pet humanization and medicalization, ensuring long-term growth. ZTS has a strong track record of market outperformance, impressive margins, and a high ROIC, making it a high-quality company. Despite the disappointing guidance for FY 2025 and the threat of possible competition, there are still plenty of growth opportunities in existing and untapped markets. Based on the earnings growth model, ZTS looks reasonably priced. Read the full article on Seeking AlphaSeeking Alpha • Mar 13
Zoetis: Focusing On The High Margin Segments
Summary The recent divestiture of the MFA segment improves margins and returns on capital. Zoetis is focusing on more profitable segments like genetics and companion animals. The recently updated Librela label includes adverse effects and urges practitioners to discuss potential adverse reactions with clients. I rate Zoetis as a buy, expecting a 10.3% investment rate of return, but I favor IDEXX for my portfolio. Read the full article on Seeking AlphaSeeking Alpha • Feb 13
Zoetis: In-Line Q4 Earnings And Weak Guidance Present A Buying Opportunity
Summary Zoetis' Q4 earnings met expectations, but the stock fell due to slowing growth and cautious 2025 guidance, presenting a buying opportunity around $163/share. Zoetis' unique advantages and pricing power in animal health, coupled with high R&D investment and a wide moat, make it a strong long-term play on emerging market growth. Despite regulatory risks and currency headwinds, Zoetis' dependable earnings and high operating margins justify a 12-month price target of $200/share. The company's diversified product portfolio and international presence position it well for sustained growth, particularly in the expanding pet care market. Read the full article on Seeking AlphaRendement voor aandeelhouders
| ZTS | US Pharmaceuticals | US Markt | |
|---|---|---|---|
| 7D | -1.6% | 1.8% | -1.1% |
| 1Y | -50.5% | 42.8% | 15.1% |
Rendement versus industrie: ZTS presteerde slechter dan de US Pharmaceuticals -sector, die het afgelopen jaar een rendement van 42.8 % opleverde.
Rendement versus markt: ZTS presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 15.1 % opleverde.
Prijsvolatiliteit
| ZTS volatility | |
|---|---|
| ZTS Average Weekly Movement | 7.6% |
| Pharmaceuticals Industry Average Movement | 9.2% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
Stabiele aandelenkoers: ZTS heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 8% ) van ZTS is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2012 | 14,500 | Kristin Peck | www.zoetis.com |
Zoetis Inc. houdt zich bezig met het ontdekken, ontwikkelen, produceren en verkopen van medicijnen, vaccins, diagnostische producten en diensten, biologische hulpmiddelen, genetische tests en precisieoplossingen voor diergezondheid voor de diergezondheidsindustrie in de Verenigde Staten en internationaal. Het bedrijf verkoopt voornamelijk producten voor gezelschapsdieren, waaronder honden, katten en paarden, en diersoorten, waaronder vee, zoals runderen, varkens, pluimvee, vissen en schapen. Het bedrijf biedt ook parasiticiden, vaccins, dermatologie, anti-infectiva, pijn en sedatie, andere farmaceutische middelen en diergezondheidsdiagnostiek.
Zoetis Inc. Samenvatting
| ZTS fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$31.26b |
| Inkomsten(TTM) | US$2.67b |
| Inkomsten(TTM) | US$9.53b |
11.8x
Koers/Winstverhouding3.3x
P/S-verhoudingIs ZTS overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| ZTS resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$9.53b |
| Kosten van inkomsten | US$2.68b |
| Brutowinst | US$6.85b |
| Overige uitgaven | US$4.18b |
| Inkomsten | US$2.67b |
Laatst gerapporteerde inkomsten
Mar 31, 2026
Volgende inkomensdatum
Aug 06, 2026
| Winst per aandeel (EPS) | 6.37 |
| Brutomarge | 71.84% |
| Nettowinstmarge | 28.03% |
| Schuld/Eigen Vermogen Verhouding | 280.3% |
Hoe presteerde ZTS op de lange termijn?
Bekijk historische prestaties en vergelijkingDividenden
2.8%
Huidig dividendrendement33%
UitbetalingsratioBetaalt ZTS een betrouwbaar dividend?
Zie ZTS dividendgeschiedenis en benchmarks| Zoetis dividenddata | |
|---|---|
| Ex Dividend Datum | Jul 20 2026 |
| Betaaldatum dividend | Sep 01 2026 |
| Dagen tot Ex-dividend | 6 days |
| Dagen tot dividendbetaaldatum | 37 days |
Betaalt ZTS een betrouwbaar dividend?
Zie ZTS dividendgeschiedenis en benchmarksBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/07/24 15:44 |
| Aandelenkoers aan het einde van de dag | 2026/07/24 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Zoetis Inc. wordt gevolgd door 39 analisten. 18 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Charles Butler | Barclays |
| Glen Santangelo | Barclays |